Cargando…
Pretransplant Hepatitis C Virus Treatment Decreases Access to High-quality Livers
BACKGROUND. Despite the revolutionary role of direct-acting antivirals for hepatitis C virus (HCV), the treatment timing for liver transplant candidates remains controversial. We hypothesize that deferring treatment until after liver transplantation improves access to a larger and higher-quality don...
Autores principales: | Strauss, Alexandra T., Ishaque, Tanveen, Weeks, Sharon, Hamilton, James P., Simsek, Cem, Durand, Christine M., Massie, Allan B., Segev, Dorry L., Gurakar, Ahmet, Garonzik-Wang, Jacqueline M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440014/ https://www.ncbi.nlm.nih.gov/pubmed/34549082 http://dx.doi.org/10.1097/TXD.0000000000001127 |
Ejemplares similares
-
Need for Pretransplant Midodrine Does Not Negatively Impact Simultaneous Liver-kidney Transplant Outcomes
por: Barman, Pranab M., et al.
Publicado: (2020) -
Magnetic Resonance Imaging Predictors of Hepatocellular Carcinoma Progression and Dropout in Patients in Liver Transplantation Waiting List
por: Baghdadi, Azarakhsh, et al.
Publicado: (2022) -
Transplant of SARS-CoV-2–infected Living Donor Liver: Case Report
por: Nguyen, Michelle C., et al.
Publicado: (2021) -
Liver Transplantation for Budd-Chiari Syndrome in the MELD Era
por: Alqahtani, Saleh A., et al.
Publicado: (2022) -
Donor BMI and Post–living Donor Liver Transplantation Outcomes: A Preliminary Report
por: Lin, Jessica S., et al.
Publicado: (2023)